Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medical Industry Hit New High In Trade Surplus

This article was originally published in PharmAsia News

Executive Summary

In the first 11 months of 2007, China's medical commodities import and export volume totaled $15.106 billion, an increase of 12.77 percent over the same period in 2006. With imports climbing 18.53 percent to $6.38 billion and exports rising 8.9 percent to $8.725 billion, the trade surplus achieved a record high of $2.345 billion. Medical devices and chemical pharmaceutical ingredients, valued at $5.945 billion and $4.052 billion respectively, dominated with 39.32 and 26.80 percent of the total trade. Chinese medicine contributed to $1.842 billion or 12.18 percent of exports, while chemical preparations occupied 10.22 percent with $1.545 billion. (Click here for more - Chinese Language)

You may also be interested in...

European Commission Decides CBD Is Not A Drug Opening Up Novel Food Pathway

The European Commission has unexpectedly concluded that CBD should not be considered as drug opening up the path to regulated EU market for the cannabinoid as a novel food.

Who’s Hired? Apotex Names New US President & CEO

As Apotex names its new US president and CEO, Akorn puts together a fresh board of directors following bankruptcy proceedings. Stada has made new appointments in Germany, while Siegfried makes significant changes in its leadership roles. 

UN Rejects Proposal To Exempt CBD From International Narcotics Controls

A WHO recommendation to explicitly exempt low-THC CBD from international narcotics controls has been emphatically rejected by UN member states. The CBD industry had hoped for a positive outcome to remove regulatory pressure on product manufacturers in Europe and around the world. 




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts